Matches in SemOpenAlex for { <https://semopenalex.org/work/W2005894868> ?p ?o ?g. }
Showing items 1 to 98 of
98
with 100 items per page.
- W2005894868 endingPage "275" @default.
- W2005894868 startingPage "271" @default.
- W2005894868 abstract "Background. Both thiotepa and its active metabolite, tepa, efficiently cross the blood-brain barrier. After intravenous administration, the cerebrospinal fluid concentrations achieved are nearly identical to those in olasma. This provides a strong rationale for testing this agent against brain tumors. Methods. Sixty pediatric patients with recurrent primary brain tumors were treated on a multiinstitutional Phase II study of intravenous thiotepa at a dose of 5 mg/m2 administered every 3 weeks. This dose is the result of a prior pediatric Phase I trial and is significantly higher than those previously recommended. Results. Three of 13 assessable patients with medul-oblastoma had partial responses lasting 22, 25, and 54 weeks. Although no objective responses were observed in 6 assessable patients with malignant gliomas and 14 with brain stem gliomas, 5 of 16 and 4 of 14 patients in elese respective strata had prolonged periods of stable isease (SD) lasting from 12 to more than 33 weeks. Nine ssessable patients with ependymoma had no objective esponse, but two had SD, both for more than 33 weeks. Myelosuppression was the principle toxic effect encoun-ered and appeared to be more severe in patients who had received prior craniospinal radiation therapy or nitro-urea therapy. Conclusions. By conventional Phase II criteria, thiotepa appears to have activity in medulloblastoma. Based on several patients with prolonged SD, it also may possess some limited activity in brain stem and malignant gliomas. The steep in vitro dose-response curve of thiotepa and the long durations of response or SD observed with the dose reported here suggest that moderate-dose to high-dose thiotepa with cytokine support or autologous bone marrow rescue may be associated with an improved response rate to this agent. Cancer 1993; 72:271–5." @default.
- W2005894868 created "2016-06-24" @default.
- W2005894868 creator A5004009909 @default.
- W2005894868 creator A5010518219 @default.
- W2005894868 creator A5018786888 @default.
- W2005894868 creator A5019914745 @default.
- W2005894868 creator A5020203091 @default.
- W2005894868 creator A5020347841 @default.
- W2005894868 creator A5024249524 @default.
- W2005894868 creator A5025567999 @default.
- W2005894868 creator A5044239219 @default.
- W2005894868 creator A5083585208 @default.
- W2005894868 creator A5083885340 @default.
- W2005894868 date "1993-07-01" @default.
- W2005894868 modified "2023-10-16" @default.
- W2005894868 title "A phase II evaluation of thiotepa in pediatric central nervous system malignancies" @default.
- W2005894868 cites W1980560578 @default.
- W2005894868 cites W2033660880 @default.
- W2005894868 cites W2034716298 @default.
- W2005894868 cites W2037946157 @default.
- W2005894868 cites W2041518082 @default.
- W2005894868 cites W2060529171 @default.
- W2005894868 cites W2089954608 @default.
- W2005894868 cites W2121896285 @default.
- W2005894868 cites W2259682466 @default.
- W2005894868 cites W2283310429 @default.
- W2005894868 cites W2478934896 @default.
- W2005894868 cites W2884633475 @default.
- W2005894868 cites W4231315714 @default.
- W2005894868 doi "https://doi.org/10.1002/1097-0142(19930701)72:1<271::aid-cncr2820720147>3.0.co;2-k" @default.
- W2005894868 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8508417" @default.
- W2005894868 hasPublicationYear "1993" @default.
- W2005894868 type Work @default.
- W2005894868 sameAs 2005894868 @default.
- W2005894868 citedByCount "55" @default.
- W2005894868 countsByYear W20058948682014 @default.
- W2005894868 countsByYear W20058948682018 @default.
- W2005894868 countsByYear W20058948682019 @default.
- W2005894868 countsByYear W20058948682020 @default.
- W2005894868 countsByYear W20058948682021 @default.
- W2005894868 crossrefType "journal-article" @default.
- W2005894868 hasAuthorship W2005894868A5004009909 @default.
- W2005894868 hasAuthorship W2005894868A5010518219 @default.
- W2005894868 hasAuthorship W2005894868A5018786888 @default.
- W2005894868 hasAuthorship W2005894868A5019914745 @default.
- W2005894868 hasAuthorship W2005894868A5020203091 @default.
- W2005894868 hasAuthorship W2005894868A5020347841 @default.
- W2005894868 hasAuthorship W2005894868A5024249524 @default.
- W2005894868 hasAuthorship W2005894868A5025567999 @default.
- W2005894868 hasAuthorship W2005894868A5044239219 @default.
- W2005894868 hasAuthorship W2005894868A5083585208 @default.
- W2005894868 hasAuthorship W2005894868A5083885340 @default.
- W2005894868 hasConcept C126322002 @default.
- W2005894868 hasConcept C141071460 @default.
- W2005894868 hasConcept C142724271 @default.
- W2005894868 hasConcept C2776694085 @default.
- W2005894868 hasConcept C2776755627 @default.
- W2005894868 hasConcept C2779429289 @default.
- W2005894868 hasConcept C2779434656 @default.
- W2005894868 hasConcept C2779968505 @default.
- W2005894868 hasConcept C2780789225 @default.
- W2005894868 hasConcept C2781432949 @default.
- W2005894868 hasConcept C71924100 @default.
- W2005894868 hasConcept C90924648 @default.
- W2005894868 hasConceptScore W2005894868C126322002 @default.
- W2005894868 hasConceptScore W2005894868C141071460 @default.
- W2005894868 hasConceptScore W2005894868C142724271 @default.
- W2005894868 hasConceptScore W2005894868C2776694085 @default.
- W2005894868 hasConceptScore W2005894868C2776755627 @default.
- W2005894868 hasConceptScore W2005894868C2779429289 @default.
- W2005894868 hasConceptScore W2005894868C2779434656 @default.
- W2005894868 hasConceptScore W2005894868C2779968505 @default.
- W2005894868 hasConceptScore W2005894868C2780789225 @default.
- W2005894868 hasConceptScore W2005894868C2781432949 @default.
- W2005894868 hasConceptScore W2005894868C71924100 @default.
- W2005894868 hasConceptScore W2005894868C90924648 @default.
- W2005894868 hasIssue "1" @default.
- W2005894868 hasLocation W20058948681 @default.
- W2005894868 hasLocation W20058948682 @default.
- W2005894868 hasOpenAccess W2005894868 @default.
- W2005894868 hasPrimaryLocation W20058948681 @default.
- W2005894868 hasRelatedWork W192857679 @default.
- W2005894868 hasRelatedWork W1976996740 @default.
- W2005894868 hasRelatedWork W1985938472 @default.
- W2005894868 hasRelatedWork W2005894868 @default.
- W2005894868 hasRelatedWork W2009174295 @default.
- W2005894868 hasRelatedWork W2054008043 @default.
- W2005894868 hasRelatedWork W2099577209 @default.
- W2005894868 hasRelatedWork W2144953909 @default.
- W2005894868 hasRelatedWork W2416576497 @default.
- W2005894868 hasRelatedWork W3044639626 @default.
- W2005894868 hasVolume "72" @default.
- W2005894868 isParatext "false" @default.
- W2005894868 isRetracted "false" @default.
- W2005894868 magId "2005894868" @default.
- W2005894868 workType "article" @default.